Abstract
Pulmonary arterial hypertension (PAH) is a progressive disease characterised by lung endothelial cell dysfunction and vascular remodelling. A number of studies now suggest that endothelial progenitor cells (EPCs) may induce neovascularisation and could be a promising approach for cell based therapy for PAH. On the contrary EPCs may contribute to pulmonary vascular remodelling, particularly in end-stage pulmonary disease. This review article will provide a brief summary of the relationship between PAH and EPCs, the application of the EPCs to PAH and highlight the potential clinical application of the EPCs cell therapy to PAH
Original language | English |
---|---|
Pages (from-to) | 595-601 |
Number of pages | 7 |
Journal | Heart Lung and Circulation |
Volume | 23 |
Issue number | 7 |
DOIs | |
Publication status | Published - Jul 2014 |